general talk, page-98

Further.

I have been surprised by the response to CBD in patients I have treated with refractory pain issues. Its anecdotal, not evidence, but we will find that out soon enough. It exceeded my expectations and it would personally surprise me if it was not effective. This primarily refers to cases where cannabinoids were not an explicit request - so I did not feel there was an expectation bias from them. I have run into the problem of epidyolex being prohibitively expensive. RX5 is the icing on the cake. Cannabinoids and their analogues are going to be interesting. Paracetamol has a cannabinoid mechanism mediated by AM404 (I've contributed to the wiki on it in my free time haha) and I have over time come to see that CB1 and 2 are probably underappreciated targets in pain management.

Even if RX5 didnt have a promising result, I feel EMD will be best positioned to explore different cannabinoids.